Thus, it would be interesting to include in our classification another marker, such as NF1, MET or YKL-40, which are characteristic of this class of GBM [9], [10], in order to derive a third subtype, thereby improving the clinical significance of our classification. This evidence concerns the gene MET and glioblastoma.